Extending the shelf life of fruit: Ugandan entrepreneurs Sandra Namboozo and Samuel Muyita in top 10 innovators of the Young Inventors Prize 2025
Namboozo and Muyita's sachets keep fruit fresh by up to extra 30 days, reducing waste and boosting farmer incomes
The pair are among top ten innovators for the Young Inventors Prize, awarded by the European Patent Office (EPO) on 18 June 2025
MUNICH, May 13, 2025 /PRNewswire/ -- Over 1 billion tonnes of food are wasted annually, while 783 million people face hunger, according to the United Nations Framework Convention on Climate Change (UNFCCC). Ugandan entrepreneurs Sandra Namboozo (26) and Samuel Muyita (27), founders of Karpolax, have developed a plant-based sachet that extends the shelf life of fresh fruit by up to 30 days. Their sustainable, biodegradable preservation solution has earned them a place in top 10 innovators in the Young Inventors Prize 2025, known as Tomorrow Shapers, which recognises young inventors tackling global challenges. They were selected from 450 candidates by an independent jury.
Sustainable preservation and fresher produce
Despite the steady increase in the global population, around 40% of all food produced does not reach the market, according to the World Wildlife Fund.
Namboozo and Muyita both grew up in farming families and saw first-hand the challenges of post-harvest losses, which have a devastating impact on the profit of small-scale farmers. Determined to find a natural and more affordable alternative to synthetic preservers, they developed sachets, which release a blend of plant-derived volatile organic compounds (VOCs) to slow ripening and prevent spoilage. The compounds – extracted from cloves, lemongrass, eucalyptus and wintergreen – inhibit ethylene production, the natural gas responsible for fruit ripening, and offer protection against mould, fungi and bacteria. Their solution allows for the controlled, sustained release of these compounds, tailored to different fruit types, thereby providing a biodegradable alternative to conventional artificial preservers.
Pilot tests conducted with Uganda's National Agricultural Research Organization showed that mangoes stored with the sachets remained fresh for 33 days, while those without them lasted only 11 days. The sachets have since been successfully used on bananas, apples, and oranges. With an affordable price point, Karpolax's sachets are particularly suited to smallholder farmers and local markets, offering a cost-effective and locally accessible way to reduce food waste and increase earnings.
Protecting innovation for lasting impact
"Farmers are one of our biggest customer groups. We wanted to use our knowledge and technical skills to develop something that would not just end on a paper in a lab but really be used by somebody," explains Namboozo.
The duo met while studying at Makerere University in Kampala, where they quickly bonded over a shared ambition to reduce food waste. They launched Karpolax in 2020 and aim to expand its reach across Africa, targeting Kenya, Rwanda and beyond. "Starting from zero, you need to source for that funding yourself. We had some supervisors from the university who supported us and made us feel confident that we could succeed," added Muyita.
By 2023, Karpolax had already worked with over 100 farmers, 20 exporters and 250 market vendors. The company is now expanding its product line to include sachets for pineapples, capsicum and berries.
The Young Inventors Prize celebrates worldwide innovators 30 and under using technology to address global challenges posed by the United Nations Sustainable Development Goals (SDGs). Namboozo and Muyita's work supports SDG 2 (Zero Hunger) by reducing post-harvest losses and SDG 12 (Responsible Consumption and Production) by promoting sustainable food preservation practices.
The prizes of the 2025 edition will be announced during a ceremony livestreamed from Iceland on 18 June 2025.
Find more information about the invention's impact, the technology and the inventor's story here.About the Young Inventors Prize
Aimed at individuals 30 and under, the Young Inventors Prize showcases the transformative power of youth-driven solutions and recognises the remarkable young people paving the way to a more sustainable future. Established in 2022, trophies were first handed out during the European Inventor Award ceremony. From 2025 onwards, the Prize will move up a gear with its own dedicated event, held separately from the Award. Among the 10 Tomorrow Shapers selected for each edition, three will be awarded a special prize: World Builders, Community Healers, and Nature Guardians. In addition, a People's Choice winner, voted by the public online, will be revealed. Each Tomorrow Shaper will receive EUR 5 000, the three special prize winners will each receive an extra EUR 15 000. The People's Choice winner will be awarded an additional EUR 5 000. Read more on the Young Inventors Prize eligibility and selection criteria.
About the EPO
With 6,300 staff members, the European Patent Office (EPO) is one of the largest public service institutions in Europe. Headquartered in Munich with offices in Berlin, Brussels, The Hague and Vienna, the EPO was founded with the aim of strengthening co-operation on patents in Europe. Through the EPO's centralised patent granting procedure, inventors are able to obtain high-quality patent protection in up to 46 countries, covering a market of some 700 million people. The EPO is also the world's leading authority in patent information and patent searching.
View original content:https://www.prnewswire.com/news-releases/extending-the-shelf-life-of-fruit-ugandan-entrepreneurs-sandra-namboozo-and-samuel-muyita-in-top-10-innovators-of-the-young-inventors-prize-2025-302452756.html
SOURCE European Patent Office (EPO)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14-07-2025
- Yahoo
CARsgen Successfully Defends Its GPC3 CAR-T Patent at the EPO
SHANGHAI, July 13, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: a company focused on developing innovative CAR T-cell therapies, announces a favorable outcome in opposition proceedings before the European Patent Office (EPO) concerning its European patent EP3445407, which covers its GPC3-targeted CAR-T cell therapy. On July 3, 2025, a U.S.-based biotechnology — the sole appellant among the original two opponents — formally withdrew its appeal against the EPO Opposition Division's earlier decision to maintain the patent. This withdrawal renders the EPO's decision final and binding for the opponents, effectively concluding their part in the opposition process. The patent was granted by the EPO in 2022 and opposed by two parties in 2023. Following oral proceedings, the EPO Opposition Division issued a decision to maintain the patent in amended form, upholding key claims related to the use of GPC3 CAR-T cell therapy following cyclophosphamide and fludarabine lymphodepletion pretreatment, in the treatment of liver cancer, lung cancer, ovarian cancer, breast cancer, gastric cancer, and thyroid cancer. Following the decision, only one opponent filed an appeal within the allowable period. That appeal has now been withdrawn. Under EPO procedures, the opponents or any other third party can no longer challenge the patent at the EPO. This development further reinforces CARsgen's intellectual property position in the field of GPC3-targeted CAR-T therapies, a promising and innovative approach for the treatment of solid tumors. About CARsgen Therapeutics Holdings Limited CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen's mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable. Forward-looking Statements All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group's current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group's control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading "Principal Risks and Uncertainties" in our most recent annual report and interim report and other announcements and reports made available on our corporate website, No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release. Contact CARsgen For more information, please visit View original content to download multimedia: SOURCE CARsgen Therapeutics
Associated Press
14-07-2025
- Associated Press
CARsgen Successfully Defends Its GPC3 CAR-T Patent at the EPO
SHANGHAI, July 13, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: a company focused on developing innovative CAR T-cell therapies, announces a favorable outcome in opposition proceedings before the European Patent Office (EPO) concerning its European patent EP3445407, which covers its GPC3-targeted CAR-T cell therapy. On July 3, 2025, a U.S.-based biotechnology — the sole appellant among the original two opponents — formally withdrew its appeal against the EPO Opposition Division's earlier decision to maintain the patent. This withdrawal renders the EPO's decision final and binding for the opponents, effectively concluding their part in the opposition process. The patent was granted by the EPO in 2022 and opposed by two parties in 2023. Following oral proceedings, the EPO Opposition Division issued a decision to maintain the patent in amended form, upholding key claims related to the use of GPC3 CAR-T cell therapy following cyclophosphamide and fludarabine lymphodepletion pretreatment, in the treatment of liver cancer, lung cancer, ovarian cancer, breast cancer, gastric cancer, and thyroid cancer. Following the decision, only one opponent filed an appeal within the allowable period. That appeal has now been withdrawn. Under EPO procedures, the opponents or any other third party can no longer challenge the patent at the EPO. This development further reinforces CARsgen's intellectual property position in the field of GPC3-targeted CAR-T therapies, a promising and innovative approach for the treatment of solid tumors. About CARsgen Therapeutics Holdings Limited CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen's mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable. Forward-looking Statements All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group's current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group's control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading 'Principal Risks and Uncertainties' in our most recent annual report and interim report and other announcements and reports made available on our corporate website, No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release. Contact CARsgen For more information, please visit View original content to download multimedia: SOURCE CARsgen Therapeutics
Associated Press
08-07-2025
- Associated Press
Tom Oda Appointed USRA Fellow--The Organization's Highest Internal Recognition of Scientific and Technical Excellence
WASHINGTON, July 8, 2025 /PRNewswire/ -- In a rare and distinguished honor, Dr. Tomohiro Oda has been named a USRA Fellow—Universities Space Research Association's highest internal accolade for extraordinary scientific and technical contributions. He joins an eminent group of just two other scientists who currently hold this title. The USRA Fellows program recognizes USRA's most distinguished scientific and technical staff for their sustained accomplishments. Appointments to this distinction are determined by the Fellows' Committee, which includes the Vice President of Science and Technology, two members of the Board of Trustees, the Chief Executive Officer, and the Chief Human Resources Officer. Dr. Elsayed Talaat, President and CEO of USRA, noted, 'Being named a USRA Fellow is a significant honor, and it reflects not only scientific excellence but also a career dedicated to advancing knowledge and impact. We are incredibly proud of Dr. Tomohiro Oda for his well-deserved recognition. His work continues to inspire scientists and advance scientific endeavors.' Dr. Oda, who serves as Interim Director of the Earth from Space Institute, is an internationally recognized expert in anthropogenic greenhouse gas (GHG) emissions. With more than 15 years of experience, his research integrates satellite remote sensing, atmospheric modeling, and emissions inventory approaches to advance global understanding of the carbon cycle and support science-based climate mitigation. He is the architect of a widely used, high-resolution global carbon emissions dataset that supports atmospheric CO₂ simulations and informs policy and scientific communities worldwide. In collaboration with leading space agencies, Dr. Oda has developed and delivered value-added environmental data products, including GHG emission maps and nighttime environmental datasets derived from satellite observations. Dr. Oda's work has had a significant influence at the global policy level. He was selected to serve on the U.S. National Academies' Consensus Study Committee on GHG Information and currently serves as a Lead Author for the Intergovernmental Panel on Climate Change (IPCC) 2027 Methodology Report on Inventories for Short-lived Climate Forcers. He leads USRA's observer delegation to the United Nations Framework Convention on Climate Change (UNFCCC) COP conferences, where he plays a key role in facilitating dialogue among scientists, policymakers, and global stakeholders. In 2023, Dr. Oda was honored with the President's Distinguished Service Award, USRA's highest level of individual recognition, in acknowledgment of his sustained excellence and impact. He joined USRA in 2014. He has authored more than 40 publications in international journals with over 7000 citations. He earned his Ph.D. in Engineering from Osaka University, Osaka, Japan. He joins previous USRA Fellows Dr. William (Bill) Meyer and Dr. Davide Venturelli as the third USRA Fellow. About USRA Universities Space Research Association operates scientific institutes and conducts major research and workforce development programs, engaging the government, academic, and industrial communities. Founded in 1969, under the auspices of the National Academy of Sciences at the request of the U.S. Government, the Universities Space Research Association is a nonprofit corporation chartered to advance space-related science, technology, and engineering. PR Contact: Suraiya Farukhi [email protected] 443-812-6945 View original content to download multimedia: SOURCE Universities Space Research Association
